AvidinOX™ for tissue targeted delivery of biotinylated cells

AvidinOX?, a product containing aldehyde groups, generated by ligand-assisted sugar oxidation of avidin by sodium periodate, maintains the capacity to bind biotin with very high affinity and exhibits the property to chemically link cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks. In recent studies, we have shown that AvidinOX exhibits much higher persistency in the skeletal muscle than native avidin. The aim of the present study is to evaluate whether AvidinOX-biotin interaction might be exploited to target biotinylated cells to an AvidinOX pre-treated muscle. To accomplish this we performed the following experiments: 1) The proliferation and differentiation properties of biotinylated C2C12 myoblasts were tested in vitro upon linkage to AvidinOX; 2) Bone marrow-derived cells (BMDC) were isolated from GFP positive transgenic mice [strain C57 BL/6-tg (UBC-GFP)] and after biotinylation (bBMDC) were intravenously administered to naive and MAVA+ (Mouse anti Avidin Antibody) C57/B6 mice previously injected with AvidinOX in a tibial muscle (TM). Localization efficiency of GFP+ bBMDC was evaluated on serial sections of the AvidinOX- and vehicle-treated (contra lateral limb) TM, 5 days after transplantation. Results show that biotinylated C2C12 cells, once linked to AvidinOX, maintain their proliferation and differentiation capacity, in vitro. Intravenous injection of biotinylated GFP+ bone marrow-derived cells leads to their specific and efficient localization in the AvidinOX-pre-treated, but not contra lateral muscle of both naive and MAVA+ mice. The present data suggest a potential use of AvidinOX to improve tissue targeted delivery of biotinylated cells.     

Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma

Conditional growth inhibition of murine Ehrlich carcinoma (EC) and B16 melanoma (B16Mel) was observed, following treatment of mice (Swiss and C57BL/6) with aqueous extract of neem (Azadirachta indica) (1 unit/mice/week for 4 weeks) either before or after inoculation of 1 x 10(6) tumor cells. Tumor inoculation after weekly injections for 4 weeks with neem leaf preparation (NLP) induced significant reduction of tumor growth (both EC and B16Mel) and increased survivability of mice. On the other hand, NLP treatment after tumor inoculation demonstrated no tumor growth inhibition in the NLP treated group in comparison to the PBS treated control. No direct cytotoxic effect of NLP towards EC and B16Mel tumor cells was observed in vitro. The spleen cells of NLP treated mice when mixed with inoculum of B16Mel tumor cells and injected into a group of mice, tumor growth was found to be significantly reduced and survivability of the tumor hosts increased remarkably in comparison to mice inoculated with tumor along with normal spleen cells. Concanavalin A (ConA) induced proliferation of lymphocytes from NLP treated mice was significantly higher than the lymphocytes of untreated mice. In in vitro, NLP by itself had no proliferative effects on lymphocytes but it co-stimulated ConA induced mitogenesis. NLP induced lymphocytosis as evidenced by increased lymphocyte count in blood as well as spleen. Flow cytometric evidence suggested that increase in CD4+ and CD8+ T cells accounted for lymphocytosis. The conditional tumor growth retardation, observed in mice treated with NLP before tumor inoculation, may be regulated by NLP mediated immune activation, having prominent role in the cellular immune function of the tumor host.     

叶酸修饰的聚乙烯亚胺-聚乙二醇共聚物载体在体内外转染效率的研究

目的探讨叶酸修饰的不同相对分子质量聚乙酰亚胺构建的聚乙烯亚胺-聚乙二醇5000(PEI-PEG)作为基因载体在体内外的转染效率。方法在体外实验中,分别测试3个相对分子质量FPPs(branched PEI:0.6kDa,10kDa和Linear PEI 25kDa)在最佳N/P、有无血清、血清的浓度和叶酸受体靶向性等条件下对口腔癌上皮细胞(KB)转染率的影响;在体内实验中,FPP(0.6kDa)分别压缩pLuc-p53基因形成的复合物通过瘤内注射和尾静脉注射2种方式考察聚合物的转染效率。结果在体外实验中,转染率最佳条件分别是N/P=20、有血清且转染率随着白蛋白(ALB)或胎牛血清(FBS)浓度的增加有上升趋势;其中3个相对分子质量PEI组成的FPP转染率分别为FPP(10kDa>25kDa>0.6kDa);FPP有较强的叶酸靶向性;在体内实验中,与BPP/pLuc和PEI(25kDa)/pLuc相比,FPP(10kDa)/pLuc呈现出较高的转染率;在48h内,随着时间的推移,转染效率增加;FPP(10kDa)/p53能改善荷瘤小鼠;与裸pLuc相比,3种相对分子质量的FPPs没有毒性。结论具有靶向性的FPP非病毒载体能成为临床传递基因治疗载体的候选。     

Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors

Neuromuscular blocking drugs produce muscle weakness by interaction with nicotinic-acetylcholine receptors. Cardiovascular side effects have been reported. In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+/-0.07+blocker 0.04+/-0.02; gallamine (21 nM), atropine 0.42+/-0.05+blocker 0.15+/-0.04; pancuronium(21 nM), atropine 0.36+/-0.03+blocker 0.03+/-0.01). These data indicate that vecuronium, gallamine and pancuronium interact with an allosteric site on the muscarinic M2 receptor (located on the heart) and this may explain some of their cardiac side effects.     

Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells

Summary Balb/c × DBA/2 F₁ mice (CD2F₁ mice) bearing L1210 lymphatic leukemia (10 L1210 cells i.p. injected on day 0) were subjected to chemoimmunotherapy. They received 100 mg/kg of cyclophosphamide i.p. on day + 8 and 10⁶ or 10⁷ immunogenic L1210 cells treated in vitro with mafosfamide — ASTA Z7654 (L1210-Maf cells) i.p. or i.p. + s.c. on days 0, + 3, + 6, + 9, + 12 after the leukemia implantation.About 30% of leukemia-bearing mice receiving cyclophosphamide and L1210-Maf cells after L1210 inoculation were able to reject the leukemia (as compared with 0% after injection of L1210-Maf cells only or 5% after cyclophosphamide administration). Better results (54% of cured mice) were obtained if 10⁷ L1210-Maf cells were injected i.p. + s.c. beside cyclophosphamide. Biological response modifiers (BRM's): levamisole, BCG, bestatin did not improve these results in the doses used in the experiment.Augmentation of anti-L1210 therapeutic response is dependent on the administration of cyclophosphamide and L1210-Maf cels. Cyclophosphamide not only reduces the tumor burden but probably can potentiate the L1210-Maf dependent antitumor immunity as well.     

Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine

Immunogenecity of the poorly immunogenic B16 melanoma cell surface antigen (B16MelSAg) was enhanced by combining B16MelSAg with NLP in C57BL/6 mice, as evidenced by ELISA and flow cytometry. NLP was as effective as Freund's complete and incomplete adjuvant to generate antibodies recognizing the B16MelSAg. The NLP generated antibody was a gamma globulin with a subtype of IgG1. Splenic lymphocytes from B16MelSAg+NLP treated mice proliferated more rapidly in vitro when stimulated by specific (B16MelSAg) and nonspecific (ConA) stimulators, in comparison to the proliferation detected in B16MelSAg and NLP treated groups. Vaccination of mice with B16MelSAg+NLP more efficiently prevented the growth of B16 melanoma tumor than mice immunized with B16MelSAg or NLP alone. In another experiment, the immune sera (B16MelSAg+NLP) was mixed with B16Mel tumors and injected subcutaneously into syngenic C57BL/6 mice. Tumor burden was less in mice receiving a tumor along with B16MelSAg+NLP generated immune sera than other groups. The B16MelSAg+NLP generated immune sera induced antibody dependent cellular cytotoxicity specifically towards B16Mel tumor cells in vitro. We concluded that NLP might be a potential immune adjuvant for inducing active immunity towards tumor antigens.     

合欢皮乙醇提取物对荷瘤小鼠IL-2生物活性的影响

目的：观察合欢皮乙醇提取物对荷瘤小鼠IL－2生物活性的影响，探讨其体内抗肿瘤机制，方法：采用EL－4细胞株建立C57 BL／6小鼠荷瘤模型，在不同时间给予合欢皮乙醇提取物腹腔注射，观察其对荷瘤小鼠IL－2生物活性的影响。结果：荷瘤小鼠造模后给药组IL－2的生物活性明显高于模型对照组（P＜0．05），结论：合欢皮乙醇提取物能对荷瘤小鼠IL－2的生物活性具有显著增强作用，提示该药在荷瘤鼠体内的抗瘤活性与其免疫增强作用有关。     

人胚肺成纤维细胞c-Ha-ras~(V12G)基因转染细胞系促癌剂检测模型的建立

为建立一个促癌剂检测模型 ,采用电穿孔法 ,将突变的c Ha rasV12G 基因转入人胚肺成纤维细胞WI 38中 ,将获得的G4 18抗性 (G4 18r)单克隆细胞株进行DNADot 印迹及RT PCR分析后 ,进一步用佛波醇酯 (PMA)处理 ,并选用克隆形成率 ,锚着独立性生长及裸鼠成瘤性等表型改变对受试细胞进行了恶性程度检测 .结果表明 :在促癌剂PMA作用下 ,WI38基因转染细胞发生了恶性转化 ,c Ha rasV12G基因使细胞对PMA的促癌敏感性增强 .由此可见 ,该模型可直接用于促癌剂的检测     

赖氨匹林对B16黑色素瘤的增殖抑制及促凋亡作用

目的探讨赖氨匹林(aspisol)在体外和体内对小鼠B16黑色素瘤细胞的增殖抑制和诱导凋亡作用。方法利用MTT法和流式细胞术检测赖氨匹林对B16细胞的增殖抑制和诱导凋亡作用。用细胞悬液法将B16黑色素瘤细胞接种于小鼠前肢腋窝皮下,制备可移植肿瘤模型。次日给予不同浓度的赖氨匹林腹腔注射,每天1次,共28天,用达卡巴嗪(dacarbazine,DTIC)和生理盐水分别作阳性对照和阴性对照。计算aspisol的抑瘤率;原位凋亡检测法(TUNEL)检测赖氨匹林对肿瘤细胞凋亡的影响;免疫组化法检测aspisol对小鼠肿瘤组织的Survivin、C-erbB-2表达的影响。结果Aspisol可抑制B16细胞增殖,最大抑制率为(68.78±1.27)%,诱导B16细胞凋亡,最大凋亡率为15.8%。200、400、800mg·kg-1aspisol对小鼠黑色素瘤的抑瘤率分别为15.0%、32.3%、49.4%,40mg·kg-1DTIC的抑瘤率为51.4%。各给药组肿瘤细胞均呈现明显凋亡形态改变,不同浓度aspisol均明显下调小鼠肿瘤组织的Survivin、C-erbB-2表达。结论Aspisol在体外和体内能够抑制小鼠B16黑色素瘤增殖和诱导凋亡,其机制可能与抑制Survivin、C-erbB-2表达有关。     

Antitumor activity ofBifidobacterium spp. isolated from a healthy Korean

The antitumor activity of Bifidobacterium breve K-110, and K-111, and B. infantis K-525 was investigated. These Bifidobacterial cells and their cell wall preparations (WPG) significantly increased the survival rate of mice who had been intraperitoneally implanted with sarcoma 180 cells. Solid tumor growth was inhibited even when the sarcoma 180 cells were implanted into the groins of the mice. However, the Bifidobacterial cells did not show in vitro cytotoxicity against tumor cell lines. Cell kinetic studies revealed that these WPGs induced neutrophils, which were followed by macrophages, at the site of peritoneal injection. The WPGs directly activated these cells to inhibit the growth of tumor cells in in vitro assays. Our results suggest that Bifidobacterial WPGs induce and activate nonspecific phagocytes in situ to reject growing tumor cells in the mouse peritoneal cavity.     

Potent and selective inhibition of the human Na+/H+ exchanger isoform NHE1 by a novel aminoguanidine derivative T-162559.

We isolated Na+/H+ exchanger (NHE)-deficient Chinese hamster ovary (CHO-K1) cells stably expressing human NHE isoforms (hNHE1, hNHE2 and hNHE3) and established an assay system for measuring their Na+/H+ exchange activity by monitoring intracellular pH alterations. Using this assay system, we demonstrated that the acylguanidine derivatives, cariporide and eniporide, cause selective inhibition of hNHE1 (IC50 value of 30 nM for cariporide, IC50 value of 4.5 nM for eniporide). Furthermore, we found that a novel synthetic aminoguanidine derivative, T-162559 ((5E,7S)-[7-(5-fluoro-2-methylphenyl)-4-methyl-7,8-dihydro-5(6H)-quinolinylideneamino] guanidine dimethanesulfonate), causes a selective inhibition of hNHE1 with more potent activity than cariporide and eniporide (IC50 value of 0.96 nM). This compound did not affect Na+/HCO3- cotransport and Na+/Ca2+ exchange.     

Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice

CpG are powerful drugs activating the innate immune system. In this study, the ability of their intramammary administration in impeding the devastating progression of carcinogenesis in all the mammary glands of female BALB/c mice transgenic for the rat neu transforming oncogene was assessed. Starting when in situ carcinomas were scattered over all their mammary glands (week 10), mice received CpG injections in the stroma of the fourth left gland. Local neoplastic progression was inhibited by six monthly administrations. CpG not only delayed the onset of carcinomas in the injected gland, but also hampered their progression. Extended latency was observed for tumors in glands both close to and far from the injection site. When the experiment ended (week 45), no tumors were palpable in 67% of the injected glands and a markedly impaired tumor growth was evident in the others. An impressive local infiltrate of CD11b(+) cells with the morphologic features of macrophages, plasma cells, B220(+) B cells, and CD4(+) and CD8(+) T cells was quickly recruited to the CpG-treated glands. High quantities of IFN-gamma producing cells were only present in the ipsilateral axillary draining lymph nodes of the treated glands. Enhanced natural killer (NK) lytic activity was also detected in the spleens. Inhibition of progression was weaker when only four injections were given, and abolished by in vivo depletion of NK cells. CpG monotherapy is thus effective in an aggressive model of autochthonous cancer. The results strongly support the administration of CpG as a local monotherapy of multiple invasive microscopic lesions.     

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

Dysfunctional N-methyl-d-aspartate (NMDA) receptor neurotransmission has been implicated in the pathophysiology of schizophrenia. It is thought that this abnormal functioning can be corrected by increasing availability of the NMDA co-agonist glycine through inhibition of glycine transporter type 1 (GlyT1). Herein is described the pharmacologic profile of RG1678, a potent and noncompetitive glycine reuptake inhibitor. In vitro, RG1678 noncompetitively inhibited glycine uptake at human GlyT1 with a concentration exhibiting half-maximal inhibition (IC(50)) of 25 nM and competitively blocked [(3)H]ORG24598 binding sites at human GlyT1b in membranes from Chinese hamster ovary cells. In hippocampal CA1 pyramidal cells, RG1678 enhanced NMDA-dependent long-term potentiation at 100 nM but not at 300 nM. In vivo, RG1678 dose-dependently increased cerebrospinal fluid and striatal levels of glycine measured by microdialysis in rats. Additionally RG1678 attenuated hyperlocomotion induced by the psychostimulant d-amphetamine or the NMDA receptor glycine site antagonist L-687,414 in mice. RG1678 also prevented the hyper-response to d-amphetamine challenge in rats treated chronically with phencyclidine, an NMDA receptor open-channel blocker. In the latter experiment, a decrease in ex vivo striatal [(3)H]raclopride binding was also measured. These data demonstrate that RG1678 is a potent, noncompetitive glycine reuptake inhibitor that can modulate both glutamatergic and dopaminergic neurotransmission in animal experiments that model aspects of schizophrenia. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'.     

Inhibition of gap junctional intercellular communication in human teratocarcinoma cells by organochlorine pesticides

Inhibition of intercellular communication, as measured by metabolic cooperation between 6-thioguanine-sensitive and 6-thioguanine-resistant Chinese hamster V79 cells, has been previously shown to be correlated with a large variety of known tumor promoters, including some of the organochlorine pesticides. Since further evidence concerning the effects of those known or suspected animal tumor promoters on human cells is needed, three organochlorine pesticides, dieldrin, aldrin, and 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT), were tested for their ability to inhibit metabolic cooperation between 6-thioguanine-sensitive (6TGs, HTP3-4) and 6-thioguanine-resistant (6TGr, HTXTG-1) human teratocarcinoma cells. Similar to the effect of the known mouse skin tumor promoter 12-tetradecanoyl phorbol-13-acetate (TPA), all three pesticides inhibited gap junctional intercellular communication within a noncytotoxic dose range. The dose-response curves of these chemicals were similar to those of other known tumor promoters on Chinese hamster V79 cells. In addition, the transfer of [3H]uridine between teratocarcinoma cells in contact was reduced after pesticide treatment.     

Synthesis and preliminary biological evaluations of CC-1065 analogues: effects of different linkers and terminal amides on biological activity

CC-1065 analogues possessing a biologically active CBI functional group and amide-substituted indole and benzofuran were synthesized. The IC(50) values of compounds 26, bearing two indoles, and 25, bearing only one indole, are 0.4 and 3 nM, respectively, against U937 leukemia cells in vitro. The IC(50) values of compounds 28, bearing a butyramino group, and 27, bearing an acetamino group, are 0.008 and 0.4 nM, respectively, against U937 leukemia cells in vitro. Compound 29, bearing a double-bond linker, is about 4-fold more potent than 25, bearing no double-bond linker. Compound 26 is highly potent against all cell lines tested in the NCI in vitro screening with IC(50) values in the 0.1-5 nM range for most cell lines. Compounds 26 and 30 are highly active against L1210 leukemia in mice. Compound 26 is also active against B16BL6 melanoma in mice. Most importantly, 26 and 30 are not myelosuppressive at therapeutically effective doses. The mechanism of tumor cell death is through induction of apoptosis, and is accompanied by DNA fragmentation.     

Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice

In order to develop a relevant xenogenic animal model of neuroblastoma (NB), we compared the tumorigenicity and metastatic potential of SK-N-SH and SK-N-DZ NB cell lines in nude mice and NOD/SCID Il2rg null (NSG) mice. Subcutaneous injection of cell lines induced tumor formation only in NSG mice and was accompanied by metastasis to the liver, adrenal glands, skull and bone marrow. NSG mice injected intravenously showed a profile of distant metastasis that was not observed in nude mice. In addition, tumor growth rates and organ infiltration patterns associated with injected NB cell lines correlated with the in vitro proliferation properties and genetic markers of poor prognosis in NB patients. We also showed that cisplatin chemotherapy was able to inhibit tumor growth. These results clearly demonstrate the higher tumorigenic and metastatic potential of NB cells in NSG mice. Therefore, this xenograft NB model should prove useful in testing the efficacy of new therapeutic approaches for NB.     

Effect of Low Doses of Low-Let Radiation on the Innate Anti-Tumor Reactions in Radioresistant and Radiosensitive Mice

BALB/c and C57BL/6 mice differ in their Th1/Th2 lymphocyte and M1/M2 macrophage phenotypes, radiosensitivity, and post-irradiation tumor incidence. In this study we evaluated the effects of repeated low-level exposures to X-rays on the development of artificial tumor colonies in the lungs of animals from the two strains and cytotoxic activities of natural killer (NK) cells and macrophages obtained from these mice. After ten daily irradiations of BALB/c or C57BL/6 mice with 0.01, 0.02, and 0.1 Gy X-rays NK cell-enriched splenocytes collected from the animals demonstrated significant and comparable up-regulation of their anti-tumor cytotoxic function. Likewise, peritoneal macrophages collected from the two irradiated strains of mice exhibited the similarly stimulated cytotoxicities against susceptible tumor cells and produced significantly more nitric oxide. These results were accompanied by the significantly reduced numbers of the neoplastic colonies induced in the lungs by intravenous injection of syngeneic tumor cells. The obtained results indicate that ten low-level irradiations with X-rays stimulate the generally similar anti-tumor reactions in BALB/c and C57BL/6 mice.     

缓释型顺铂瘤内治疗大鼠C6胶质瘤的药代动力学

目的　观察C6胶质瘤大鼠瘤内给予顺铂缓释剂 ,ip顺铂后 ,顺铂在瘤内、脑组织、血及肾中的分布。方法　瘤内给予 1mg·m- 2 顺铂缓释剂 ,ip 5 0mg·m- 2顺铂后 ,然后在不同时间取样 ,用原子吸收分光光度法测量顺铂含量。结果　瘤内顺铂浓度瘤内用药比全身用药平均高 2～ 5 0倍 ,血及肾中的顺铂浓度瘤内用药仅为全身用药的 1.6 %～ 10 %和 0 .4 5 %～ 14 %。结论　瘤内用顺铂缓释剂可明显提高局部药物浓度 ,降低血 ,肾中顺铂分布 ,减轻全身毒副作用 ,从而增强化疗效果     

肺肿瘤小鼠MDSC、 Treg 及传统T 细胞变化研究

摘要： 目的 探讨肺肿瘤小鼠骨髓源性抑制细胞 （MDSC）、 调节性 T 细胞 （Treg） 和传统 T 细胞的变化及机制。方法 采用配对设计将 20 只 C57BL/6 小鼠随机均分为 Lewis 肺癌细胞注射组 （LLC 组） 和正常对照组 （NC 组）, LLC 组采用皮下注射 LLC 细胞 100 μL （1×106 ） 制备肺肿瘤小鼠模型, 对照组注射等量生理盐水。待肿瘤形成后取小鼠脾细胞, 采用流式细胞仪检测肺肿瘤小鼠 MDSC、 Treg 及 CD4+ 和 CD8+ T 细胞比例和数量变化, 膜联蛋白-V （Annexin-Ⅴ）染色检测 CD4+ 和 CD8+ T 细胞凋亡变化, 5-溴脱氧尿嘧啶核苷 （BrdU） 染色检测 CD4+ 和 CD8+ T 细胞增殖变化。结果 与 NC 组相比, LLC 组脾脏 MDSC 比例和数量明显增加, CD4+ Foxp3+ Treg 所占 CD4+ T 细胞比例和数量明显增加,而 CD4+ 和 CD8+ T 细胞所占脾细胞比例和数量明显降低 （均 P < 0.05）。与 NC 组相比, LLC 组 CD4+ 和 CD8+ T 细胞增殖明显降低, 同时 CD8+ T 细胞凋亡明显增加 （P < 0.05）。结论 MDSC 和 Treg 细胞在肺肿瘤小鼠数量增加, 同时, MDSC 和Treg 抑制 CD4+ 和CD8+ T 细胞增殖, 并促进 CD8+ T 细胞凋亡。     

人甲胎蛋白启动子控制HIV-1 Vpr表达的重组腺病毒体内抑瘤效果研究

目的：研究人甲胎蛋白启动子控制表达HIV Vpr基因的重组腺病毒对裸鼠肝癌模型的肿瘤组织生长抑制作用，探讨其应用于肝癌基因治疗的可行性。方法：将人甲胎蛋白启动子控制表达HIV Vpr基因的重组腺病毒（rvAdAFP-Vpr）直接注射到利用BEL-7402细胞建立的肝癌裸鼠模型瘤体内，同时往裸鼠腹腔内注射环磷酰胺（CTX），经过1个月的治疗，利用肿瘤生长曲线、增殖指数、凋亡指数等指标，观察rvAdAFP-Vpr对肝癌组织生长抑制的效果。结果：人甲胎蛋白启动子控制表达HIV Vpr基因的重组腺病毒在肝癌组织中表达了Vpr蛋白，rvAdAFP-Vpr注射明显诱导肿瘤细胞凋亡，抑制了体内肝癌组织的生长，rvAdAFP-Vpr治疗组和rvAdAFP-Vpr＋CTX治疗组抑瘤率分别达到41％和66．7％，与空白对照组和rvAd-null组相比，具有统计学意义，差异显著（P〈0．05，P〈0．01），两组的Ki-67指数和凋亡指数相比，对照组和空腺病毒载体（rvAd-null）组同样具有统计学意义，差异显著（P〈0．05，P〈0．01）。结论：人甲胎蛋白启动子控制表达HIV Vpr基因的重组腺病毒rvAdAFP-Vpr通过引起肝癌细胞凋亡，有效抑制了体内肝癌组织的生长。本研究结果为HIV-1 Vpr应用于肝癌治疗提供了依据。